Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
PharmaMar
ClinicalTrials.gov Identifier:
NCT01831089
First received: April 2, 2013
Last updated: July 26, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2016
  Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)